CytoSorbents (CSTO) Bullish View Reiterated at Maxim Group on Commercial Launch of CytoSorb for Cardiac Surgery
Tweet Send to a Friend
Maxim Group analyst Jason Kolbert reiterated a Buy rating and $8 price target on CytoSorbents (NASDAQ: CTSO) after the company ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
